Nalaganje...
Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycles with the possibility to double the dose in the first 12 weeks of the first cycle. Durin...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2009
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3218722/ https://ncbi.nlm.nih.gov/pubmed/22096350 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|